Skip to content
Article Rich – Lifestyle
Author:
Basilea Pharmaceutica International Ltd, Allschwil
Basilea shareholders approve all proposals of the board of directors at the 2026 annual general meeting
April 15, 2026
Basilea awarded additional CARB-X funding of USD 6 million to support the clinical development of antibiotic BAL2420
April 9, 2026
Basilea announces start of first‑in‑human study of novel antibiotic BAL2420
March 23, 2026
Basilea receives further USD 6 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
March 4, 2026